{"id":58663,"date":"2026-03-03T14:05:26","date_gmt":"2026-03-03T06:05:26","guid":{"rendered":"https:\/\/flcube.com\/?p=58663"},"modified":"2026-03-03T14:05:27","modified_gmt":"2026-03-03T06:05:27","slug":"hua-medicines-dorzagliatin-wins-hong-kong-approval-first-in-class-gka-enters-market-for-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58663","title":{"rendered":"Hua Medicine&#8217;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes"},"content":{"rendered":"\n<p><strong>Hua Medicine (<a href=\"https:\/\/www.google.com\/finance\/quote\/2552:HKG\">HKG:\u202f2552<\/a>)<\/strong> announced that the <strong>Department of Health in Hong Kong<\/strong> has approved <strong>HuaTangNing (dorzagliatin tablets)<\/strong> for the treatment of <strong>type 2 diabetes in adults<\/strong>. The <strong>first\u2011in\u2011class glucokinase activator (GKA)<\/strong> represents a <strong>novel mechanism<\/strong> targeting <strong>glucose homeostasis restoration<\/strong> through <strong>multi\u2011organ metabolic enhancement<\/strong>, expanding Hua Medicine&#8217;s <strong>Greater China commercial footprint<\/strong> beyond mainland China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hua Medicine (HKG:\u202f2552)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HuaTangNing (dorzagliatin tablets)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>First\u2011in\u2011class glucokinase activator (GKA)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>Department of Health, Hong Kong<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Marketing authorization for type 2 diabetes<\/td><\/tr><tr><td><strong>Prior Approvals<\/strong><\/td><td>Mainland China (NRDL inclusion Jan\u202f2024)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-glucokinase-activation\">Mechanism of Action \u2013 Glucokinase Activation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Function<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>Glucokinase (GK) \u2013 glucose sensor enzyme in pancreatic \u03b2\u2011cells, liver, intestine<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Repairs impaired GK function and expression \u2192 restores glucose sensitivity<\/td><\/tr><tr><td><strong>Therapeutic Effect<\/strong><\/td><td>Improves glucose homeostasis dysregulation at the source<\/td><\/tr><tr><td><strong>Multi\u2011Organ Action<\/strong><\/td><td>Pancreas (insulin secretion), intestine (GLP\u20111 release), liver (glucose uptake)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mainland-china-registration\">Mainland China Registration<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>T2D Monotherapy (na\u00efve patients)<\/strong><\/td><td>Approved; first\u2011line use<\/td><\/tr><tr><td><strong>T2D Combination (with metformin)<\/strong><\/td><td>Approved; when metformin monotherapy inadequate<\/td><\/tr><tr><td><strong>Reimbursement<\/strong><\/td><td><strong>National Reimbursement Drug List (NRDL)<\/strong> \u2013 Jan\u202f2024<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Differentiation:<\/strong> Dorzagliatin is the <strong>world&#8217;s first approved GKA<\/strong>, positioning Hua Medicine as a <strong>pioneer in glucose\u2011sensing pharmacology<\/strong> with <strong>mechanistic differentiation<\/strong> from GLP\u20111 agonists, SGLT2 inhibitors, and DPP\u20114 inhibitors.<\/li>\n\n\n\n<li><strong>Greater China Expansion:<\/strong> <strong>Hong Kong approval<\/strong> enables <strong>commercial launch<\/strong> in a <strong>high\u2011value market<\/strong> with <strong>premium pricing potential<\/strong> and <strong>regulatory credibility<\/strong> supporting future <strong>Asia\u2011Pacific expansion<\/strong>.<\/li>\n\n\n\n<li><strong>Source\u2011Level Glucose Control:<\/strong> The <strong>GK activation mechanism<\/strong> addresses <strong>glucose sensitivity at the cellular level<\/strong>, potentially offering <strong>disease\u2011modifying benefits<\/strong> vs. symptomatic glucose lowering\u2014supporting <strong>long\u2011term positioning<\/strong> in T2D management evolution.<\/li>\n\n\n\n<li><strong>NRDL Validation:<\/strong> <strong>Mainland China NRDL inclusion<\/strong> (Jan\u202f2024) validates <strong>reimbursement acceptability<\/strong> and <strong>volume potential<\/strong>; Hong Kong launch leverages <strong>manufacturing scale<\/strong> and <strong>clinical data package<\/strong> already established.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Hong Kong T2D Market<\/strong><\/td><td>~\u202f300,000 diagnosed patients; high\u2011value private and public hospital segments; preference for innovative mechanisms<\/td><\/tr><tr><td><strong>GKA Competitive Position<\/strong><\/td><td>No direct competitors; complementary to GLP\u20111\/SGLT2 standard of care; potential for combination therapy<\/td><\/tr><tr><td><strong>Asia\u2011Pacific Expansion<\/strong><\/td><td>Hong Kong approval supports <strong>regulatory harmonization<\/strong> for Singapore, Malaysia, and other markets seeking innovative diabetes therapies<\/td><\/tr><tr><td><strong>Hua Medicine Valuation<\/strong><\/td><td>First\u2011in\u2011class status + dual\u2011market approval (China + Hong Kong) supports <strong>partnership attractiveness<\/strong> and <strong>licensing potential<\/strong> for global markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hong Kong commercial launch timelines, prescription uptake, and Asia\u2011Pacific expansion for dorzagliatin. Actual results may differ due to risks including competitive GLP\u20111 dominance, pricing negotiations with Hong Kong Hospital Authority, and long\u2011term cardiovascular outcome data requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,1159,308,15],"class_list":["post-58663","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-diabetes","tag-hkg-2552","tag-hua-medicine","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hua Medicine&#039;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing (dorzagliatin tablets) for the treatment of type 2 diabetes in adults. The first\u2011in\u2011class glucokinase activator (GKA) represents a novel mechanism targeting glucose homeostasis restoration through multi\u2011organ metabolic enhancement, expanding Hua Medicine&#039;s Greater China commercial footprint beyond mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58663\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hua Medicine&#039;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing (dorzagliatin tablets) for the treatment of type 2 diabetes in adults. The first\u2011in\u2011class glucokinase activator (GKA) represents a novel mechanism targeting glucose homeostasis restoration through multi\u2011organ metabolic enhancement, expanding Hua Medicine&#039;s Greater China commercial footprint beyond mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58663\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T06:05:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T06:05:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58663#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58663\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hua Medicine&#8217;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes\",\"datePublished\":\"2026-03-03T06:05:26+00:00\",\"dateModified\":\"2026-03-03T06:05:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58663\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"HKG: 2552\",\"Hua Medicine\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58663#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58663\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58663\",\"name\":\"Hua Medicine's Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-03T06:05:26+00:00\",\"dateModified\":\"2026-03-03T06:05:27+00:00\",\"description\":\"Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing (dorzagliatin tablets) for the treatment of type 2 diabetes in adults. The first\u2011in\u2011class glucokinase activator (GKA) represents a novel mechanism targeting glucose homeostasis restoration through multi\u2011organ metabolic enhancement, expanding Hua Medicine's Greater China commercial footprint beyond mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58663#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58663\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58663#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hua Medicine&#8217;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hua Medicine's Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing (dorzagliatin tablets) for the treatment of type 2 diabetes in adults. The first\u2011in\u2011class glucokinase activator (GKA) represents a novel mechanism targeting glucose homeostasis restoration through multi\u2011organ metabolic enhancement, expanding Hua Medicine's Greater China commercial footprint beyond mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58663","og_locale":"en_US","og_type":"article","og_title":"Hua Medicine's Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes","og_description":"Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing (dorzagliatin tablets) for the treatment of type 2 diabetes in adults. The first\u2011in\u2011class glucokinase activator (GKA) represents a novel mechanism targeting glucose homeostasis restoration through multi\u2011organ metabolic enhancement, expanding Hua Medicine's Greater China commercial footprint beyond mainland China.","og_url":"https:\/\/flcube.com\/?p=58663","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T06:05:26+00:00","article_modified_time":"2026-03-03T06:05:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58663#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58663"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hua Medicine&#8217;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes","datePublished":"2026-03-03T06:05:26+00:00","dateModified":"2026-03-03T06:05:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58663"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","HKG: 2552","Hua Medicine","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58663#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58663","url":"https:\/\/flcube.com\/?p=58663","name":"Hua Medicine's Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-03T06:05:26+00:00","dateModified":"2026-03-03T06:05:27+00:00","description":"Hua Medicine (HKG:\u202f2552) announced that the Department of Health in Hong Kong has approved HuaTangNing (dorzagliatin tablets) for the treatment of type 2 diabetes in adults. The first\u2011in\u2011class glucokinase activator (GKA) represents a novel mechanism targeting glucose homeostasis restoration through multi\u2011organ metabolic enhancement, expanding Hua Medicine's Greater China commercial footprint beyond mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58663#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58663"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58663#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hua Medicine&#8217;s Dorzagliatin Wins Hong Kong Approval \u2013 First\u2011in\u2011Class GKA Enters Market for Type 2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58663"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58663\/revisions"}],"predecessor-version":[{"id":58666,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58663\/revisions\/58666"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}